<DOC>
	<DOCNO>NCT02031419</DOCNO>
	<brief_summary>First study , multiple clinical center , explore effect different combination compound ( CC-122 , CC-223 , CC-292 rituximab ) treat Diffuse Large B Cell Lymphoma ( DLBCL )</brief_summary>
	<brief_title>Novel Combinations CC-122 , CC-223 , CC-292 , Rituximab Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Study CC-122-DLBCL-001 Phase 1b dose escalation expansion clinical study CC 122 , CC-223 CC-292 administer orally doublet without rituximab , subject relapsed/refractory DLBCL fail standard therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Biopsy proven Diffuse large Bcell lymphoma ( DLBCL ) ( include transform low grade lymphoma ) Relapsed refractory prior standard treatment regimens At least one site measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Subjects must follow laboratory value : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ≥ 1.0 x 109/L ( bone marrow involvement DLBCL ) Hemoglobin ( Hgb ) ≥ 8 g/dL . Potassium within normal limit Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase ( AST/SGOT ) Alanine Aminotransferase/Serum GlutamicPyruvic Transaminase ( ALT/SGPT ) ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 5.0 X ULN liver tumor present . Serum bilirubin ≤ 1.5 x ULN . Estimated serum creatinine clearance ≥ 50 mL/min Subjects must follow laboratory value : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L without growth factor support 7 day ( 14 day subject receive pegfilgrastim ) . Males enrol treatment arm receive CC122 must : Agree abstain donate sperm take IP least 3 month follow discontinuation IP Symptomatic central nervous system involvement . Known symptomatic acute chronic pancreatitis . Persistent diarrhea malabsorption despite medical management . Peripheral neuropathy ≥ grade 2 Impaired cardiac function clinically significant cardiac disease Subjects diabetes active treatment ( subject treat CC223 contain arm ) Prior autologous stem cell transplant ( ASCT ) ≤ 3 month first dose . Prior allogeneic stem cell transplant either standard reduce intensity conditioning . Prior systemic cancerdirected treatment investigational modality ≤ 5 half live 4 week prior start study drug , whichever short . Subjects undergone major surgery ≤ 2 week prior start study drug . Women pregnant breast feeding . Adults reproductive potential willing employ two form birth control . Subjects know HIV infection , chronic active hepatitis B C virus ( HBV/HCV ) infection . Subjects treatmentrelated myelodysplastic syndrome . History concurrent second cancer require active , ongoing systemic treatment . Prior treatment dual mTORC1/mTORC2 inhibitor ( CC223 arm ) BTK inhibitor ( PCI32765 ) ( CC292 arm ) . [ Prior treatment rapamycin analogue , PI3K AKT inhibitor , lenalidomide rituximab allow ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CC-122</keyword>
	<keyword>CC-223</keyword>
	<keyword>CC-292</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
</DOC>